By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Biotechnology. According to news reporting originating from Uppsala, Sweden, by NewsRx editors, the research stated, "Both the development and regulation of pharmaceutical dosage forms have undergone significant improvements and development over the past 25 years, due primarily to the extensive application of the biopharmaceutical classification system (BCS). The Biopharmaceutics Drug Disposition Classification System, which was published in 2005, has also been a useful resource for predicting the influence of transporters in several pharmacokinetic processes."
Our news editors obtained a quote from the research from Uppsala University, "However, there remains a need for the pharmaceutical industry to develop reliable in vitro/in vivo correlations and in silica methods for predicting the rate and extent of complex gastrointestinal (GI) absorption, the bioavailability, and the plasma concentration time curves for orally administered drug products. Accordingly, a more rational approach is required, one in which high quality in vitro or in silico characterizations of active pharmaceutical ingredients and formulations are integrated into physiologically based in silica biopharmaceutics models to capture the full complexity of GI drug absorption. The need for better understanding of the in vivo GI process has recently become evident after an unsuccessful attempt to predict the GI absorption of BCS class II and IV drugs. Reliable data on the in vivo permeability of the human intestine (P-eff) from various intestinal regions is recognized as one of the key biopharmaceutical requirements when developing in silico GI biopharmaceutics Models with improved predictive accuracy. The P-eff values for human jejunum and ileum, based on historical open, single-pass, perfusion studies are presented in this review."
According to the news editors, the research concluded: "The main objective of this review is to summarize and discuss the relevance and current status of these human in vivo regional intestinal permeability values."
For more information on this research see: Human in Vivo Regional Intestinal Permeability: Importance for Pharmaceutical Drug Development. Molecular Pharmaceutics, 2014;11(1):12-23. Molecular Pharmaceutics can be contacted at: Amer Chemical Soc, 1155 16TH St, NW, Washington, DC 20036, USA. (American Chemical Society - www.acs.org; Molecular Pharmaceutics - www.pubs.acs.org/journal/mpohbp)
The news editors report that additional information may be obtained by contacting H. Lennernas, Uppsala University, Dept. of Pharmaceut, S-75312 Uppsala, Sweden (see also Biotechnology).
Keywords for this news article include: Biotechnology, Sweden, Europe, Uppsala, Therapy, Drug Development, Biopharmaceuticals
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC